Short Interest in Oragenics, Inc. (NYSEAMERICAN:OGEN) Grows By 39.0%

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the recipient of a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling 792,779 shares, an increase of 39.0% from the February 26th total of 570,220 shares. Based on an average daily trading volume, of 442,572 shares, the days-to-cover ratio is currently 1.8 days. Currently, 20.3% of the company’s stock are short sold.

Oragenics Price Performance

NYSEAMERICAN OGEN traded down $0.05 during mid-day trading on Friday, reaching $0.53. The stock had a trading volume of 76,015 shares, compared to its average volume of 295,748. The stock has a market cap of $2.30 million, a PE ratio of -0.04 and a beta of 1.09. Oragenics has a 1 year low of $0.52 and a 1 year high of $9.60. The company has a fifty day moving average price of $0.78 and a 200 day moving average price of $0.98.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Clear Street LLC purchased a new position in shares of Oragenics during the 2nd quarter worth $270,000. Bank of America Corp DE increased its stake in shares of Oragenics by 7,374.0% in the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after purchasing an additional 15,338 shares in the last quarter. Sabby Management LLC bought a new position in Oragenics in the 3rd quarter worth $77,000. DRW Securities LLC raised its holdings in Oragenics by 82.4% in the 4th quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock worth $88,000 after purchasing an additional 50,900 shares during the period. Finally, XTX Topco Ltd purchased a new position in Oragenics during the fourth quarter valued at $26,000. 18.71% of the stock is owned by hedge funds and other institutional investors.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.